<DOC>
	<DOCNO>NCT02517905</DOCNO>
	<brief_summary>This Phase 3 , randomize , double-blind , placebo-controlled study subject schedule undergo elective bilateral third molar extraction local anesthesia . At least one low mandibular third molar must involve full partial bony impaction confirm visual radiographic evidence .</brief_summary>
	<brief_title>Evaluation EXPAREL Prolonged Postsurgical Analgesia Subjects Undergoing Third Molar Extraction</brief_title>
	<detailed_description>Subjects screen within 30 day prior surgery . Randomized subject receive dental nerve block lidocaine 2 % epinephrine 1:100,000 undergoing bilateral third molar extraction local anesthesia . In addition lidocaine nerve block , Investigator may choose add topical benzocaine intraoperative nitrous oxide . At end surgery , least 20 minute lidocaine administration , blind study drug infiltrate provide postsurgical analgesia . Subjects require remain research facility 96 hour study drug administration . Postsurgical efficacy , safety , pharmacokinetic ( PK ) assessment conduct . All subject return follow-up visit Days 7 10 . A phone call make subject Day 30 adverse event ( AE ) assessment inquire whether subject make unscheduled phone call office visit relate pain .</detailed_description>
	<mesh_term>Toothache</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>1 . Male female , ≥18 year age screening . 2 . Scheduled undergo bilateral third molar extraction ( i.e. , extraction four third molar ) local anesthesia . At least one low mandibular third molar must involve full partial bony impaction confirm visual radiological evidence . 3 . American Society Anesthesiology ( ASA ) physical status 1 , 2 , 3 . 4 . Female subject must either surgically sterile , use medically acceptable method birth control , least 2 year postmenopausal , must document negative pregnancy test result screen Day 1 prior surgery . 5 . Able provide inform consent , adhere study visit schedule , complete study assessment . 1 . History hypersensitivity idiosyncratic reaction amidetype local anesthetic opioids . 2 . Contraindication lidocaine , epinephrine , bupivacaine , oxycodone . 3 . History significant drug allergy ( e.g. , anaphylaxis hepatotoxicity ) . 4 . Positive test result urine drug screen screen prior surgical procedure . 5 . Currently pregnant , nursing , plan become pregnant study within 1 month study drug administration . 6 . History active psychiatric illness ( include major depression , bipolar disorder , anxiety ) ; Type 1 Type 2 diabetes ; severe renal hepatic impairment ; significant cardiovascular disease ( include cardiac rhythm disturbance ) ; migraine headache , frequent headache , pain condition , medical condition , opinion Investigator , may increase risk surgery interfere evaluation study drug . 7 . History infection require intravenous ( IV ) antibiotic within 45 day oral ( PO ) antibiotic within 30 day prior study drug administration reason dental prophylaxis . Subjects must afebrile , without sign symptom indicative active infection . 8 . Use following medication within time specify surgery : longacting opioid medication , nonsteroidal antiinflammatory drug ( NSAIDs ) , aspirin ( except lowdose aspirin use cardioprotection ) , acetaminophen within 3 day , opioid medication within 24 hour . 9 . Initiation treatment follow medication within 1 month EXPAREL infiltration medication ( ) give control pain : selective serotonin reuptake inhibitor ( SSRIs ) , selective norepinephrine reuptake inhibitor ( SNRIs ) , gabapentin , pregabalin ( Lyrica® ) , duloxetine ( Cymbalta® ) . If subject take one medication reason pain control , must stable dose least 1 month prior EXPAREL administration . 10 . Current use systemic glucocorticosteroids within 1 month enrollment study . 11 . Use concurrent therapy could interfere evaluation efficacy safety , drug Investigator 's opinion may exert significant analgesic property act synergistically investigational product . 12 . Administration investigational drug within 30 day 5 elimination halflives investigational drug , whichever longer , prior study drug administration , plan administration another investigational product procedure subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>